Kinnate Biopharma Inc.
Kinnate Biopharma Inc. (KNTE) Stock Overview
Explore Kinnate Biopharma Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
125M
P/E Ratio
-1.10
EPS (TTM)
$-2.78
ROE
-0.59%
KNTE Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Kinnate Biopharma Inc. (KNTE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.85.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.10 and a market capitalization of 125M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.